Table 2 AEs of anti-angiogenesis drugs related studies
From: Re-evaluating the risk factors for radiation pneumonitis in the era of immunotherapy
Drugs | Study | Published year | study type | No. of cases | Radiation dose(Gy) | AEs rate(%) |
|---|---|---|---|---|---|---|
Bevacizumab | Wang C [66] | 2019 | Clinical Trial | 88 | 84 | > 3Grade: 22 fatal events:11 |
Lind.J S [68] | 2012 | Clinical Trial | 6 | 66 | RP:83 > 3Grade: 33 | |
Swog S0533 [71] | 2015 | Clinical Trial | 29 | 64 | > 3Grade: 9.0 fatal events:9.0 | |
Endostatin | Zhang S L [73] | 2020 | Meta-analysis | 271 | 60–66 | RP: ECRT:10.9;ERT:9.4%RE: ECRT:11.6;ERT:12.2 |
Zhai Y (HELP study) [74] | 2019 | Clinical Trial | 73 | 60–66 | RP:11.9 > 3Grade: 58.2 5Grade: 2 | |
Anlotinib | Baohui H (ALTER 0303) [77] | 2018 | Clinical Trial | 296 | / | Hemoptysis ACC:1.3;SCC10.6 |
Zhu H [79] | 2022 | Clinical Trial | 7 | 54–66 | RP:83 fatal events:28.57 |